Literature DB >> 22186795

Progress toward in vivo use of siRNAs-II.

Garrett R Rettig1, Mark A Behlke.   

Abstract

RNA interference (RNAi) has been extensively employed for in vivo research since its use was first demonstrated in mammalian cells 10 years ago. Design rules have improved, and it is now routinely possible to obtain reagents that suppress expression of any gene desired. At the same time, increased understanding of the molecular basis of unwanted side effects has led to the development of chemical modification strategies that mitigate these concerns. Delivery remains the single greatest hurdle to widespread adoption of in vivo RNAi methods. However, exciting advances have been made and new delivery systems under development may help to overcome these barriers. This review discusses advances in RNAi biochemistry and biology that impact in vivo use and provides an overview of select publications that demonstrate interesting applications of these principles. Emphasis is placed on work with synthetic, small interfering RNAs (siRNAs) published since the first installment of this review which appeared in 2006.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22186795      PMCID: PMC3293614          DOI: 10.1038/mt.2011.263

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  302 in total

1.  Functional studies of the PI(3)-kinase signalling pathway employing synthetic and expressed siRNA.

Authors:  Frank Czauderna; Melanie Fechtner; Hüseyin Aygün; Wolfgang Arnold; Anke Klippel; Klaus Giese; Jörg Kaufmann
Journal:  Nucleic Acids Res       Date:  2003-01-15       Impact factor: 16.971

2.  Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA.

Authors:  Katalin Karikó; Michael Buckstein; Houping Ni; Drew Weissman
Journal:  Immunity       Date:  2005-08       Impact factor: 31.745

3.  Nanoparticle-mediated delivery of siRNA targeting Parp1 extends survival of mice bearing tumors derived from Brca1-deficient ovarian cancer cells.

Authors:  Michael S Goldberg; Deyin Xing; Yin Ren; Sandra Orsulic; Sangeeta N Bhatia; Phillip A Sharp
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-27       Impact factor: 11.205

4.  Local RNA target structure influences siRNA efficacy: systematic analysis of intentionally designed binding regions.

Authors:  Steffen Schubert; Arnold Grünweller; Volker A Erdmann; Jens Kurreck
Journal:  J Mol Biol       Date:  2005-05-13       Impact factor: 5.469

5.  Naked siLNA-mediated gene silencing of lung bronchoepithelium EGFP expression after intravenous administration.

Authors:  Sys Zoffmann Glud; Jesper B Bramsen; Frederik Dagnaes-Hansen; Jesper Wengel; Kenneth Alan Howard; Jens R Nyengaard; Jørgen Kjems
Journal:  Oligonucleotides       Date:  2009-06

6.  UNA (unlocked nucleic acid): a flexible RNA mimic that allows engineering of nucleic acid duplex stability.

Authors:  Niels Langkjaer; Anna Pasternak; Jesper Wengel
Journal:  Bioorg Med Chem       Date:  2009-06-27       Impact factor: 3.641

7.  Structural requirements of double-stranded RNA for the activation of 2',5'-oligo(A) polymerase and protein kinase of interferon-treated HeLa cells.

Authors:  M A Minks; D K West; S Benvin; C Baglioni
Journal:  J Biol Chem       Date:  1979-10-25       Impact factor: 5.157

8.  Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms.

Authors:  Akin Akinc; William Querbes; Soma De; June Qin; Maria Frank-Kamenetsky; K Narayanannair Jayaprakash; Muthusamy Jayaraman; Kallanthottathil G Rajeev; William L Cantley; J Robert Dorkin; James S Butler; Liuliang Qin; Timothy Racie; Andrew Sprague; Eugenio Fava; Anja Zeigerer; Michael J Hope; Marino Zerial; Dinah W Y Sah; Kevin Fitzgerald; Mark A Tracy; Muthiah Manoharan; Victor Koteliansky; Antonin de Fougerolles; Martin A Maier
Journal:  Mol Ther       Date:  2010-05-11       Impact factor: 11.454

9.  Silencing of hypoxia inducible factor-1alpha by RNA interference attenuates human glioma cell growth in vivo.

Authors:  David L Gillespie; Kum Whang; Brian T Ragel; Jeannette R Flynn; David A Kelly; Randy L Jensen
Journal:  Clin Cancer Res       Date:  2007-04-15       Impact factor: 12.531

10.  Direct CNS delivery of siRNA mediates robust silencing in oligodendrocytes.

Authors:  William Querbes; Pei Ge; Wenjun Zhang; Yupeng Fan; Jason Costigan; Klaus Charisse; Martin Maier; Lubomir Nechev; Muthiah Manoharan; Victor Kotelianski; Dinah W Y Sah
Journal:  Oligonucleotides       Date:  2009-03
View more
  85 in total

1.  Synthesis and Conjugation of Small Interfering Ribonucleic Neutral SiRNNs.

Authors:  Alexander S Hamil; Steven F Dowdy
Journal:  Methods Mol Biol       Date:  2016

2.  2'Fluoro Modification Differentially Modulates the Ability of RNAs to Activate Pattern Recognition Receptors.

Authors:  Youngju Lee; Johannes H Urban; Li Xu; Bruce A Sullenger; Jaewoo Lee
Journal:  Nucleic Acid Ther       Date:  2016-01-20       Impact factor: 5.486

3.  Nanoparticle-Delivered IRF5 siRNA Facilitates M1 to M2 Transition, Reduces Demyelination and Neurofilament Loss, and Promotes Functional Recovery After Spinal Cord Injury in Mice.

Authors:  Jun Li; Yanbin Liu; Haidong Xu; Qiang Fu
Journal:  Inflammation       Date:  2016-10       Impact factor: 4.092

4.  Conjugation of palmitic acid improves potency and longevity of siRNA delivered via endosomolytic polymer nanoparticles.

Authors:  Samantha M Sarett; Kameron V Kilchrist; Martina Miteva; Craig L Duvall
Journal:  J Biomed Mater Res A       Date:  2015-02-27       Impact factor: 4.396

Review 5.  GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics.

Authors:  Aaron D Springer; Steven F Dowdy
Journal:  Nucleic Acid Ther       Date:  2018-05-24       Impact factor: 5.486

6.  Lipophilic siRNA targets albumin in situ and promotes bioavailability, tumor penetration, and carrier-free gene silencing.

Authors:  Samantha M Sarett; Thomas A Werfel; Linus Lee; Meredith A Jackson; Kameron V Kilchrist; Dana Brantley-Sieders; Craig L Duvall
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-24       Impact factor: 11.205

7.  Drug delivery: Puncturing cells en masse.

Authors:  Mark R Prausnitz
Journal:  Nat Mater       Date:  2015-05       Impact factor: 43.841

8.  Balancing cationic and hydrophobic content of PEGylated siRNA polyplexes enhances endosome escape, stability, blood circulation time, and bioactivity in vivo.

Authors:  Christopher E Nelson; James R Kintzing; Ann Hanna; Joshua M Shannon; Mukesh K Gupta; Craig L Duvall
Journal:  ACS Nano       Date:  2013-09-23       Impact factor: 15.881

Review 9.  Engineering better immunotherapies via RNA interference.

Authors:  Mouldy Sioud
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

10.  Therapeutic Potential of OMe-PS-miR-29b1 for Treating Liver Fibrosis.

Authors:  Virender Kumar; Vinod Kumar; Jiangtao Luo; Ram I Mahato
Journal:  Mol Ther       Date:  2018-09-01       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.